20/11/2020
Rexgenero-France (previously aratinga.bio), a preclinical stage biotech company developing an off-the-shelf and universal chimeric antigen receptor (CAR)-T therapy which allows…
Read More
11/11/2020
Rexgenero-France (previously aratinga.bio), a preclinical stage biotech company developing an off-the-shelf and universal chimeric antigen receptor (CAR)-T therapy which allows in vivo targeting…
Read More
09/04/2019
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat critical limb ischaemia (CLI), announces today…
Read More